Second chance: drug combo retested for tough colorectal cancer

NCT ID NCT07178717

Not yet recruiting Disease control Sponsor: Vall d'Hebron Institute of Oncology Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether giving the drugs encorafenib and cetuximab again can help people with a specific type of advanced colorectal cancer (BRAF V600E-mutant) whose disease got worse after prior treatment with similar drugs. About 25 participants will receive the drug combination until their cancer progresses or side effects become too severe. The main goal is to see how many patients are alive without their cancer getting worse after 4 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: encorafenib and cetuximab
What this could lead to: If successful, this could provide a new treatment option for patients with a specific type of advanced colorectal cancer whose disease has progressed after initial BRAF inhibitor therapy.
What could go wrong: This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The treatment may not control the cancer for long, and side effects from the drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLO-RECTAL CANCER

Contacts and locations

Locations

Hospital Universitari Vall d'Hebron

Barcelona, Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.